European AIDS Treatment Group·2 min read·medium
The cost of HIV drugs for Medicare is projected to skyrocket by 2035
H
https://www.facebook.com/EuropeanAIDSTreatmentGroup
✦AI Summary
A new study projects that Medicare costs for HIV antiretroviral therapy will nearly triple by 2035 as the population of people living with HIV ages. The increase is driven by longer life expectancies and rising healthcare inflation.
As more people with HIV reach retirement age, the annual cost of antiretroviral therapy (ART) for Medicare for people 65 or older is projected to nearly triple over the next decade, from $6.4 billion in 2026 to $17.8 billion by 2035.
healtheconomypolitics
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in